Published in J Clin Oncol on January 10, 2008
Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 9.86
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol (2010) 6.04
Marital status and survival in patients with cancer. J Clin Oncol (2013) 5.82
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol (2012) 3.73
Interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J Natl Cancer Inst (2012) 3.37
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int (2010) 2.59
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol (2014) 2.46
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res (2009) 1.99
IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res (2011) 1.87
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol (2015) 1.72
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol (2014) 1.70
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2010) 1.65
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol (2011) 1.55
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol (2013) 1.54
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer. Invest New Drugs (2012) 1.38
Abiraterone and other novel androgen-directed strategies for the treatment of prostate cancer: a new era of hormonal therapies is born. Ther Adv Urol (2012) 1.24
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006. Cancer (2010) 1.23
Prostate cancer in East Asia: evolving trend over the last decade. Asian J Androl (2015) 1.22
Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis (2013) 1.22
Image guided dose escalated prostate radiotherapy: still room to improve. Radiat Oncol (2009) 1.20
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology (2011) 1.15
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
How does older age influence oncologists' cancer management? Oncologist (2010) 1.10
Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol (2008) 1.09
New paradigms for advanced prostate cancer. Rev Urol (2007) 1.09
Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J Natl Cancer Inst (2012) 1.07
Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer (2015) 1.05
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol (2011) 1.05
Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett (2009) 1.04
Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Can Urol Assoc J (2011) 1.04
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol (2015) 1.04
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21. Cancer Res (2010) 1.01
Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX 327 study. Can Urol Assoc J (2013) 1.00
Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00
GLIPR1 tumor suppressor gene expressed by adenoviral vector as neoadjuvant intraprostatic injection for localized intermediate or high-risk prostate cancer preceding radical prostatectomy. Clin Cancer Res (2011) 1.00
Radium-223 chloride: a potential new treatment for castration-resistant prostate cancer patients with metastatic bone disease. Cancer Manag Res (2013) 1.00
Chemotherapy for prostate cancer: Clinical practice in Canada. Can Urol Assoc J (2013) 0.99
New players for advanced prostate cancer and the rationalisation of insulin-sensitising medication. Int J Cell Biol (2013) 0.98
Immune Infiltration and Prostate Cancer. Front Oncol (2015) 0.98
Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer. J Biol Chem (2013) 0.97
Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy. Ther Adv Urol (2014) 0.96
Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer. Genes Cancer (2011) 0.96
d -Limonene sensitizes docetaxel-induced cytotoxicity in human prostate cancer cells: Generation of reactive oxygen species and induction of apoptosis. J Carcinog (2009) 0.95
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br J Cancer (2008) 0.95
Overcoming drug resistance and treating advanced prostate cancer. Curr Drug Targets (2012) 0.95
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer (2009) 0.93
Current treatment strategies for castration-resistant prostate cancer. Korean J Urol (2011) 0.93
Management of high-risk localized prostate cancer. Adv Urol (2011) 0.93
Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol (2014) 0.92
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget (2015) 0.92
Overcoming docetaxel resistance in prostate cancer: a perspective review. Ther Adv Med Oncol (2012) 0.91
Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene (2013) 0.91
Innovations in the systemic therapy of prostate cancer. Nat Rev Clin Oncol (2009) 0.91
Prostate cancer regulatory networks. J Cell Biochem (2009) 0.91
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial. Ann Oncol (2011) 0.90
Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer. BJU Int (2011) 0.90
Tolerability and efficacy of docetaxel in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Geriatr Oncol (2014) 0.90
Nanoformulation of natural products for prevention and therapy of prostate cancer. Cancer Lett (2012) 0.90
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel. Oncotarget (2015) 0.89
Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Ther Adv Urol (2013) 0.89
Chemotherapy and its evolving role in the management of advanced prostate cancer. Asian J Androl (2014) 0.88
A Phase II Clinical Trial of Oral Valproic Acid in Patients with Castration-Resistant Prostate Cancers Using an Intensive Biomarker Sampling Strategy. Transl Oncol (2008) 0.88
Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism. Prostate (2013) 0.88
Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer. Oncotarget (2016) 0.88
Leptomeningeal metastases from prostate cancer: an emerging clinical conundrum. Clin Exp Metastasis (2009) 0.87
The natural compound Guttiferone F sensitizes prostate cancer to starvation induced apoptosis via calcium and JNK elevation. BMC Cancer (2015) 0.87
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. Br J Cancer (2011) 0.87
Current paradigms and evolving concepts in metastatic castration-resistant prostate cancer. Asian J Androl (2011) 0.87
Prostate cancer: current treatment and prevention strategies. Iran Red Crescent Med J (2013) 0.87
Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway. Adv Urol (2012) 0.86
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer. J Urol (2010) 0.86
Targeting the oncogenic protein beta-catenin to enhance chemotherapy outcome against solid human cancers. Mol Cancer (2010) 0.85
Novel options for the treatment of castration-resistant prostate cancer. World J Urol (2011) 0.85
Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res (2008) 0.85
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther (2013) 0.85
Evolving Personalized Therapy for Castration-Resistant Prostate Cancer. Biomedicine (Taipei) (2014) 0.84
CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cells. Cancer Immunol Immunother (2011) 0.84
CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids (2015) 0.84
Anakoinosis: Communicative Reprogramming of Tumor Systems - for Rescuing from Chemorefractory Neoplasia. Cancer Microenviron (2015) 0.84
Phase I Trial of Arginine Deprivation Therapy with ADI-PEG 20 Plus Docetaxel in Patients with Advanced Malignant Solid Tumors. Clin Cancer Res (2015) 0.83
Bone-targeting radiopharmaceuticals for the treatment of bone-metastatic castration-resistant prostate cancer: exploring the implications of new data. Oncologist (2014) 0.83
SIRT3 inhibits prostate cancer by destabilizing oncoprotein c-MYC through regulation of the PI3K/Akt pathway. Oncotarget (2015) 0.83
Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancer. Drug Des Devel Ther (2013) 0.83
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer. Br J Cancer (2012) 0.83
Japanese phase I study of cabazitaxel in metastatic castration-resistant prostate cancer. Int J Clin Oncol (2015) 0.83
Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T (2011) 0.82
The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol (2011) 0.82
Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer (2012) 0.82
Efficacy and safety of docetaxel plus prednisolone chemotherapy for metastatic hormone-refractory prostate adenocarcinoma: single institutional study in Korea. Cancer Res Treat (2010) 0.82
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer. J Hematol Oncol (2014) 0.82
Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer. Core Evid (2013) 0.82
Mechanisms of acquired resistance to androgen receptor targeting drugs in castration-resistant prostate cancer. Expert Rev Anticancer Ther (2014) 0.82
Update: immunological strategies for prostate cancer. Curr Urol Rep (2010) 0.82
In vivo targeting of ADAM9 gene expression using lentivirus-delivered shRNA suppresses prostate cancer growth by regulating REG4 dependent cell cycle progression. PLoS One (2013) 0.82
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med (2004) 32.09
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Drug penetration in solid tumours. Nat Rev Cancer (2006) 9.80
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med (2015) 8.80
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA (2005) 8.72
Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst (2007) 7.10
Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum (2002) 4.69
Trends in incidence and mortality in rheumatoid arthritis in Rochester, Minnesota, over a forty-year period. Arthritis Rheum (2002) 4.23
Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer (2005) 3.58
Predictors of infection in rheumatoid arthritis. Arthritis Rheum (2002) 3.47
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol (2011) 3.46
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res (2007) 3.41
Factors associated with failure to publish large randomized trials presented at an oncology meeting. JAMA (2003) 3.36
Noninvasive detection of testicular carcinoma in situ in semen using OCT3/4. Eur Urol (2007) 3.34
Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents. J Clin Oncol (2006) 3.31
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol (2007) 3.23
Measured and estimated GFR in healthy potential kidney donors. Am J Kidney Dis (2004) 3.11
Treatment of prostate cancer with intermittent versus continuous androgen deprivation: a systematic review of randomized trials. J Clin Oncol (2013) 2.92
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study. J Clin Oncol (2005) 2.83
Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. J Clin Oncol (2007) 2.79
Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2007) 2.68
Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes. J Clin Oncol (2009) 2.66
Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. J Natl Cancer Inst (2012) 2.57
Medication reconciliation at hospital discharge: evaluating discrepancies. Ann Pharmacother (2008) 2.57
Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst (2013) 2.54
Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial. J Clin Oncol (2005) 2.52
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol (2011) 2.50
Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer. J Natl Cancer Inst (2012) 2.46
Impact of wait times on survival for women with uterine cancer. J Clin Oncol (2013) 2.45
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol (2005) 2.42
The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res (2005) 2.33
Placebo effects in oncology. J Natl Cancer Inst (2003) 2.23
New therapies for castration-resistant prostate cancer: efficacy and safety. Eur Urol (2011) 2.21
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst (2007) 2.14
When are "positive" clinical trials in oncology truly positive? J Natl Cancer Inst (2010) 2.09
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
Randomized phase II trials: inevitable or inadvisable? J Clin Oncol (2010) 2.02
The price we pay for progress: a meta-analysis of harms of newly approved anticancer drugs. J Clin Oncol (2012) 1.98
Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer (2014) 1.93
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol (2007) 1.91
Disseminated intravascular coagulation as the presenting sign of metastatic prostate cancer. J Gen Intern Med (2006) 1.88
Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol (2010) 1.86
Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer. Clin Cancer Res (2009) 1.85
Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Eur Urol (2006) 1.78
Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol (2012) 1.76
Screening trials are even more difficult than we thought they were. J Natl Cancer Inst (2002) 1.76
Dermopathy of Graves' disease (pretibial myxedema): long-term outcome. J Clin Endocrinol Metab (2002) 1.73
MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials (2011) 1.71
Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer (2003) 1.70
Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research. J Clin Oncol (2007) 1.69
Long-term effects of androgen deprivation therapy in prostate cancer patients. Clin Endocrinol (Oxf) (2002) 1.64
Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials. Eur Urol (2012) 1.64
Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res (2006) 1.63
Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol (2003) 1.63
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol (2011) 1.62
The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J Am Soc Nephrol (2002) 1.60
The penetration of anticancer drugs through tumor tissue as a function of cellular adhesion and packing density of tumor cells. Cancer Res (2006) 1.58
Pharmacist medication assessments in a surgical preadmission clinic. Arch Intern Med (2007) 1.57
Trials in palliative treatment--have the goal posts been moved? Lancet Oncol (2008) 1.57
Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol (2006) 1.56
Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol (2006) 1.55
The association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. Cancer (2011) 1.55
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol (2007) 1.53
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res (2005) 1.48
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer (2009) 1.45
Enzalutamide in European and North American men participating in the AFFIRM trial. BJU Int (2014) 1.43
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res (2008) 1.43
Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol (2011) 1.43
Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol (2006) 1.42
Mathematics in the realm of lapatinib: 500 + 500 = 1,500? J Clin Oncol (2008) 1.42
Company stock prices before and after public announcements related to oncology drugs. J Natl Cancer Inst (2011) 1.42
Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital. BMC Cancer (2006) 1.41
ASCO core values. J Clin Oncol (2006) 1.40
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol (2007) 1.40
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys (2009) 1.36
Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer (2006) 1.33
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. Prostate (2009) 1.33
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy. Urol Oncol (2010) 1.31